156 related articles for article (PubMed ID: 35609920)
1. First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.
Tsundue T; Namdon T; Tsewang T; Topgyal S; Dolma T; Lhadon D; Choetso T; Woesal T; Yangkyi T; Gupta A; Peters D; Paster Z; Phunkyi D; Sadutshang TD; Chaisson RE; Dorjee K
BMJ Glob Health; 2022 May; 7(5):. PubMed ID: 35609920
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
5. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S
JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield
Murali S; Sakthivel M; Pattabi K; Venkatasamy V; Thangaraj JWV; Shete A; Varghese AJ; Arjun J; Kumar CPG; Yadav PD; Sahay R; Majumdar T; Dudhmal M; Sivalingam A; Dhanapal SR; Durai Samy A; Radhakrishnan V; Muni Krishnaiah MM; Arunachalam S; Gandhi PMK; Govindasamy E; Chinnappan P; Sekar DPV; Marappan P; Pounraj E; Ganeshkumar P; Jagadeesan M; Narnaware M; Bedi GS; Kaur P; Murhekar M
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746578
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
13. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
[TBL] [Abstract][Full Text] [Related]
14. Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
Dorjee K; Namdon T; Topgyal S; Gyatso U; Tsundue T; Dolma T; Kumar V; Lhadon D; Yangkyi T; Khachoe T; Dorjee S; Sadoff RC; Peters D; Gupta A; Paster Z; Chaisson RE; Phunkyi D; Sadutshang TD
Vaccine; 2024 Jun; 42(16):3572-3577. PubMed ID: 38679512
[TBL] [Abstract][Full Text] [Related]
15. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
Grewal R; Kitchen SA; Nguyen L; Buchan SA; Wilson SE; Costa AP; Kwong JC
BMJ; 2022 Jul; 378():e071502. PubMed ID: 35793826
[TBL] [Abstract][Full Text] [Related]
17. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
[TBL] [Abstract][Full Text] [Related]
18. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
